NEW YORK, Dec. 15, 2014 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
The following 44 securities will be added to the Index: Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), Akebia Therapeutics, Inc. (Nasdaq:AKBA), Alder BioPharmaceuticals (Nasdaq:ALDR), Alimera Sciences Inc. (Nasdaq:ALIM), Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH), ANI Pharmaceuticals, Inc. (Nasdaq:ANIP), Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), Cara Therapeutics, Inc. (Nasdaq:CARA), Compugen Ltd. (Nasdaq:CGEN), Celladon Corporation (Nasdaq:CLDN), Concert Pharmaceuticals, Inc. (Nasdaq:CNCE), Enanta Pharmaceuticals Inc. (Nasdaq:ENTA), Flamel Technologies S.A. (Nasdaq:FLML), Foundation Medicine, Inc. (Nasdaq:FMI), Amicus Therapeutics, Inc. (Nasdaq:FOLD), Five Prime Therapeutics (Nasdaq:FPRX), GW Pharmaceuticals Plc (Nasdaq:GWPH), Hyperion Therapeutics, Inc. (Nasdaq:HPTX), Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), Inovio Pharmaceuticals, Inc. (Nasdaq:INO), Insmed Inc. (Nasdaq:INSM), Kite Pharma, Inc. (Nasdaq:KITE), Karyopharm Therapeutics Inc. (Nasdaq:KPTI), MacroGenics, Inc. (Nasdaq:MGNX), Ophthotech Corporation (Nasdaq:OPHT), Pharmacyclics Inc. (Nasdaq:PCYC), Aratana Therapeutics, Inc. (Nasdaq:PETX), POZEN Inc. (Nasdaq:POZN), Pernix Therapeutics Holdings, Inc. (Nasdaq:PTX), QLT Inc. (Nasdaq:QLTI), Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), Receptos, Inc. (Nasdaq:RCPT), Radius Health, Inc. (Nasdaq:RDUS), Relypsa, Inc. (Nasdaq:RLYP), Retrophin, Inc. (Nasdaq:RTRX), Revance Therapeutics, Inc. (Nasdaq:RVNC), Sage Therapeutics, Inc. (Nasdaq:SAGE), Theravance Biopharma, Inc. (Nasdaq:TBPH), Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), Versartis, Inc. (Nasdaq:VSAR), Acceleron Pharma Inc. (Nasdaq:XLRN), Zafgen Inc. (Nasdaq:ZFGN) and ZS Pharma, Inc. (Nasdaq:ZSPH).
The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following eight securities will be removed from the Index: Amarin Corporation PLC (Nasdaq:AMRN), Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL), Curis, Inc. (Nasdaq:CRIS), Esperion Therapeutics, Inc. (Nasdaq:EXPR), Cellular Dynamics International (Nasdaq:ICEL), Onconova Therapeutics Inc. (Nasdaq:ONTX), Rigel Pharmaceuticals Inc. (Nasdaq:RIGL), and Zogenix, Inc. (Nasdaq:ZGNX).
About Nasdaq Global Indexes
Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend Achievers, Global, Nordic, Green Economy, Sharia and Commodity Indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq Global Indexes also provides custom index services and design solutions to selected financial organizations. For more information about Nasdaq Global Indexes, visit indexes.nasdaqomx.com.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or business.nasdaq.com
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
CONTACT: Media Contacts: Joseph Christinat, Nasdaq +1.646.441.5121 Josh Machiz, Nasdaq +22.214.171.12414 Issuer & Investor Contact: Natasha Selzer, Nasdaq +1.301.978.8623